Impact of pharmacist's interventions on cost of drug therapy in intensive care unit

Pharmacy Practice

Volumn 7, Issue 2, 2009, Pages 81-87

  Saokaew, Surasak ^a   Maphanta, Sirada ^a   Thangsomboon, Pomchanok ^b  

^a NARESUAN UNIVERSITY   (Thailand)

^b Bhuddachinaraj Hospital   (Thailand)

Author keywords

Cost savings; Intensive care unit; Pharmacists; Thailand

Indexed keywords

ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; ELECTROLYTE; INSULIN; PSYCHOTROPIC AGENT;

APACHE; ARTICLE; CONTROLLED STUDY; COST CONTROL; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LIQUID; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST; PROSPECTIVE STUDY; STANDARDIZATION; THAILAND;

EID: 70349207741     PISSN: None     EISSN: 18863655     Source Type: Journal    
DOI: 10.4321/S1886-36552009000200003     Document Type: Article

References (34)

1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533-543.
2. Schiff GD, Klass D, Peterson J, Shah G, Bates DW. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med. 2003;163:893-900.
3. Krupicka MI, Bratton SL, Sonnenthal K, Goldstein BG. Impact of a pediatric clinical pharmacist in the pediatric intensive care unit. Crit Care Med. 2002;30:919-921.
4. Leaps LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-70.
5. Schommer JC, Wenzel RG, Kucukarslan SN. Evaluation of pharmacists' service for hospital inpatients. Am J Health-Syst Pharm. 2002;59:1632-1637.
6. American Society of Health-System Pharmacist. ASHP guideline on the pharmacist's role in the development, implementation, and assessment of critical care pathways. Am J Health-Syst Pharm 2004;61:939-45.
7. Brilli RJ, Spevetz A, Branson RD, Campbell GM, Cohen H, Dasta JF, Harvey MA, Kelley MA, Kelly KM, Rudis MI, St Andre AC, Stone JR, Tares D, Weled BJ, American College of Critical Care Medicine Task Force on Models of Critical Care Delivery. The American College of Critical Care Medicine Guidelines for the Defintion of an Intensivist and the Practice of Critical Care Medicine. Critical care delivery in the intensive care unit: defining clinical roles and the best practice model. Crit Care Med. 2001:29:2007-2019.
8. Society of Critical Care Medicine, American College of Clinical Pharmacy. Position paper on critical care pharmacy services. Pharmacotherapy. 2000;20(11):1400-1406.
9. Kirk JK, Michael KA, Markowsky SJ, Restino NR, Zarowitz BJ. Critical pathways: the time is here for pharmacist. involvement. Pharmacotherapy. 1996;16(4):723-33.
10. Kucukarsian SN, Peters M, Mlynaerek M, Natziger DA. Pharmacist on rounding teams reduces preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003;163:2014-2018.
11. Suseno M, Tedeski L, Kent S, Rough S. Impact of documented pharmacists' interventions on patient care and cost. Hosp Pharm. 1998;33:676-681.
12. Chisholm MA, Vollenweider LJ, Mulloy LL, Jagadeesan M, Wade WE, Dipiro JT. Direct patient care services provided by a pharmacist on a multidisciplinary renal transplant team. Am J Health-Syst Pharm. 2000;57:1599-1601.
13. Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm. 2004;10(2):159-165.
14. Lim WS, Low HN, Chan SP, Chen HN, Ding YY, Tan TL. Impact of pharmacist consult clinic on hospital-based geriatric outpatient clinic in Singapore. Ann Acad Med Singapore. 2004;33:220-227.
15. Boyko WL, Yurkowski PJ, Ivey MF, Armitstead JA, Robberts YL. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health-Syst Pharm. 1997;54:1591-1595.
16. Hatoum HT, Hutchinson RA, Witte KW, Newby GP. Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm. 1988;22:252-259.
17. Zimmerman CR, Smolarek RT, Stevenson JG. A computerized system to improve documentation and reporting of pharmacists' clinical interventions, cost saving, and workload activities. Pharmacotherapy. 1995;15(2):220-227.
18. Gandhi PJ, Smith BS, Tataronis GR, Maas B. Impact of pharmacist on drug costs in a coronary care unit. Am J Health-Syst Pharm. 2001;58:497-503.
19. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services 1988-1995. Pharmacotherapy. 1996;16(6):1188-1208.
20. Zaidi STR, Hassan Y, Postma MJ, Ng SH. Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital. Pharm World Sci. 2003;25(6):299-302.
21. McMullin ST, Hennenfent JA, Ritchie DJ, Huey WY, Lonergan TP, Schaiff RA, Tonin ME, Bailey TC. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999;159:2306-2309.
22. Chuang LC, Sutton JD, Henderson GT. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit. Hosp Pharm. 1994;29(3):215-218.
23. Montazeri M, Cook DJ. Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med. 1994;22:1044-1048.
24. Brockmiller H, Abel SR, Koh-Knox CP, Birk CW. Cost impact of Pharm.D. candidates' drug therapy recommendations. Am J health-Syst Pharm. 1999;56:882-884.
25. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29:691-698.
26. Ibrahim KH, Gunderson B, Rotschafer JC. Intensive care unit antimicrobial resistance and the role of the pharmacist. Crit Care Med. 2001;29(suppl):N108-N113.
27. Pasquale TR, Komomy KM, Letting-Mangira D, Peshek S. A pharmacist-physician antibiotic support team. P&T. 2004; 29:33-40.
28. Mutnick AH, Sterba KJ, Peroutka JA, Sloan NE, Beltz EA, Sorenson MK. Cost saving and avoidance form clinical interventions. Am J Health-Syst Pharm. 1997;54:392-396.
29. Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE. Clinical and economic outcomes of pharmacist recommendations in a Verterans Affairs medical center. Am J Health-Syst Pharm. 2002;59:2070-2077.
30. Nesbit TW, Shermock KM, Bobek MB, Capozzi DL, Flores PA, Leonard MC, Long JK, Militello MA, White DA, Barone LD, Goldman MP, Kvancz DA. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health-Syst Pharm. 2001;58:784-790.
31. Boonsrarakpong N, Thadapak U, Chariyapongphaiboon P, Kidgoukarun R, Rattanawaraha K, Preechakul S, et al. Payment of adverse drug reaction in medical ward. Thai Northern Regional Hospitals Report, 2004.
32. Rosner B, editor. Fundamentals of biostatistic. 4th ed. Belmont, CA:Wadsworth; 1995.
33. Bearce WC, Willey GA, Fox RL, et al. Documentation of clinical interactions: Quality of care issues and economic considerations in critical care pharmacy. Hosp Pharm. 1988;23:544-548.
34. Warrian K, Irvine-Meek J. Cost-benefit of clinical services integrated with a decentralized unit dose system. Can J Hosp Pharm. 1988;41:109-121.